Intervacc AB (SE:IVACC)
:IVACC
Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr0.92
-kr0.06(-5.24%)
At close: 4:00 PM EST
kr0.92
-kr0.06(-5.24%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume791.15K
Average Volume (3M)373.34K
Market Cap
kr443.06M
Enterprise Valuekr301.20M
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr44.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and a sizable equity base give the company structural financial flexibility. Over the next 2–6 months this reduces bankruptcy and refinancing risk, supports continued R&D/commercialization spending, and limits immediate dilution needs if cash burn moderates.
Improving Cash Flow TrendFree cash flow has meaningfully improved versus the prior period, indicating operational progress or better cost control. If this trend persists it reduces external financing dependence and supports a durable path toward self-funding or smaller, less dilutive capital raises.
Commercialized Core ProductHaving an authorized, revenue-generating vaccine with distribution partners is a durable commercial foundation. It de-risks pure R&D exposure, provides existing sales channels to scale, and offers potential partner revenue or licensing opportunities over the medium term.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow materially shortens runway and forces reliance on external capital. Over months this creates dilution risk, constrains marketing/commercial expansion for Strangvac, and may limit the ability to fund new product development without partner financing.
Deep Operating LossesVery large negative gross and operating margins indicate either pricing or cost-structure issues and that current sales do not cover production and overhead. This structural profitability gap must be closed to achieve sustainable operations and fund growth without repeated financing.
Small, Declining Revenue BaseModest and slipping revenues limit economies of scale and make margins harder to fix; combined with negative returns on equity, continued losses can erode capital. Reliance on a single commercial product raises concentration risk if adoption or reimbursement stalls.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr443.06M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 62 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―